Physician profile
Robert A Campbell
NPI 1275505554
$3,689.14
in general payments reported to CMS, 2019-2025
36 companies · $218 in 2025
The $218 reported for 2025 was less than what a typical Colon & Rectal Surgery provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,787 · 2020: $226 · 2021: $411 · 2022: $417 · 2023: $499 · 2024: $131 · 2025: $218.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $825 · Travel and Lodging: $23.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $824.59 |
| Travel and Lodging | $23.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic USA, INC. | $963.02 | 2019 | |
| Merck Sharp & Dohme LLC | $462.95 | 2020-2025 | Bridion |
| Coloplast Corp | $363.25 | 2019-2023 | Sensura Mio, Sensura |
| Intuitive Surgical, INC. | $341.02 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $227.61 | 2019-2023 | Trulance |
| Zyla Life Sciences, INC. | $149.61 | 2019-2020 | |
| Braintree Laboratories, INC. | $144.30 | 2021-2025 | Sutab, Suflave |
| Ethicon US, LLC | $120.38 | 2019-2024 | Echelon Endopath |
| Baxter Healthcare | $76.43 | 2021-2023 | Seprafilm |
| Acacia Pharma INC | $64.00 | 2021-2022 | |
| Covidien LP | $60.85 | 2019 | |
| Stryker Corporation | $59.72 | 2023 | Spy-Phi System |
| Boston Scientific Corporation | $56.26 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $49.90 | 2021-2023 | Gattex |
| Medtronic, INC. | $46.46 | 2021-2023 | Signia |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tela Bio, INC. | $45.02 | 2023 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Mallinckrodt Enterprises LLC | $43.65 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $40.28 | 2019 | |
| Acell, INC. | $37.48 | 2019-2020 | |
| Kci USA, INC. | $35.83 | 2019-2020 | |
| Shire North American Group INC | $33.29 | 2019 | |
| Smith+Nephew, INC. | $31.82 | 2023 | Grafix |
| La Jolla Pharmaceutical Company | $22.17 | 2022 | |
| Davol INC. | $19.76 | 2021 | |
| Abbvie INC. | $18.70 | 2025 | |
| Vyaire Medical, INC. | $18.50 | 2023 | |
| Mimedx Group, INC. | $18.22 | 2025 | |
| Access Pro Medical, LLC | $18.08 | 2025 | Matriderm |
| Innovation Technologies INC | $17.52 | 2024 | Irrisept |
| Becton, Dickinson and Company | $16.53 | 2024 | Arista Ah Flexitip |
| Allergan, INC. | $16.18 | 2021 | |
| Axonics, INC. | $15.60 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $15.59 | 2025 | |
| Innocoll Pharmaceuticals Limited | $14.68 | 2021 | |
| Acera Surgical, INC. | $13.62 | 2023 | Restrata Wound Matrix |
| Monaghan Medical Corporation | $10.86 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Campbell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.